JP2019532079A - オキシステロールおよびその使用方法 - Google Patents
オキシステロールおよびその使用方法 Download PDFInfo
- Publication number
- JP2019532079A JP2019532079A JP2019520737A JP2019520737A JP2019532079A JP 2019532079 A JP2019532079 A JP 2019532079A JP 2019520737 A JP2019520737 A JP 2019520737A JP 2019520737 A JP2019520737 A JP 2019520737A JP 2019532079 A JP2019532079 A JP 2019532079A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- hydrogen
- disorder
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC1(C)C2=CC=CC=C1*C=C2 Chemical compound CC1(C)C2=CC=CC=C1*C=C2 0.000 description 11
- NCUZZFXCVIRQBW-SKDRPLOKSA-N CC[C@@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(CC)O)O Chemical compound CC[C@@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(CC)O)O NCUZZFXCVIRQBW-SKDRPLOKSA-N 0.000 description 3
- ZMBKTXPTPXLEOH-YDOJPLNBSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC1CCC(C)(C)CC1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC1CCC(C)(C)CC1)O)O ZMBKTXPTPXLEOH-YDOJPLNBSA-N 0.000 description 2
- NYPYPOZNGOXYSU-UHFFFAOYSA-N Brc1cccnc1 Chemical compound Brc1cccnc1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- NFWNBBLUYOYGCX-KDQJKQQOSA-N CC(C)CC[C@@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)[C@H]2C(CC2)[C@@H]1C[C@@]2(C)O)O Chemical compound CC(C)CC[C@@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)[C@H]2C(CC2)[C@@H]1C[C@@]2(C)O)O NFWNBBLUYOYGCX-KDQJKQQOSA-N 0.000 description 1
- HSRUDVSBHVBZAR-XACJTUTOSA-N CC(C)CC[C@@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O Chemical compound CC(C)CC[C@@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O HSRUDVSBHVBZAR-XACJTUTOSA-N 0.000 description 1
- ZJSRXRJIURSKTD-PCFYLMMQSA-N CC(C)CC[C@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(COC)O)O Chemical compound CC(C)CC[C@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(COC)O)O ZJSRXRJIURSKTD-PCFYLMMQSA-N 0.000 description 1
- PULNFUUKJPBQLR-UHFFFAOYSA-N CC1(C)C=CN=CC=C1 Chemical compound CC1(C)C=CN=CC=C1 PULNFUUKJPBQLR-UHFFFAOYSA-N 0.000 description 1
- YIILPKXEPDXULN-UHFFFAOYSA-N CC1(C)C=NN=CC=C1 Chemical compound CC1(C)C=NN=CC=C1 YIILPKXEPDXULN-UHFFFAOYSA-N 0.000 description 1
- XPELVUGXPQRMMT-ZLMIFYAYSA-N CCC(C)(C(C)CCC[C@H](C)C(C(F)(F)F)O)O Chemical compound CCC(C)(C(C)CCC[C@H](C)C(C(F)(F)F)O)O XPELVUGXPQRMMT-ZLMIFYAYSA-N 0.000 description 1
- SHWLCNPFWIHDAE-KLTUBFHYSA-N CCC(CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C=O)O Chemical compound CCC(CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C=O)O SHWLCNPFWIHDAE-KLTUBFHYSA-N 0.000 description 1
- NCUZZFXCVIRQBW-ILCYOCDHSA-N CCC([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(CC)O)O Chemical compound CCC([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(CC)O)O NCUZZFXCVIRQBW-ILCYOCDHSA-N 0.000 description 1
- PLTQRVRCCCUHIN-KESATFQXSA-N CCCC/C=C/CCCO[C@@](CC)(CC1)C[C@H]2[C@@]1(C)[C@]1(CC[C@@](C)([C@@H](CC3)C4)[C@H]3[C@H](C)[C@@H](CC3CCC(C)(C)CC3)O)C4C1CC2 Chemical compound CCCC/C=C/CCCO[C@@](CC)(CC1)C[C@H]2[C@@]1(C)[C@]1(CC[C@@](C)([C@@H](CC3)C4)[C@H]3[C@H](C)[C@@H](CC3CCC(C)(C)CC3)O)C4C1CC2 PLTQRVRCCCUHIN-KESATFQXSA-N 0.000 description 1
- PNACJJFJWYBPBA-WTTBNOFXSA-N CCCC[C@@H](C)CC[C@H](C)[C@H](CC1)C[C@H]1C(C)=O Chemical compound CCCC[C@@H](C)CC[C@H](C)[C@H](CC1)C[C@H]1C(C)=O PNACJJFJWYBPBA-WTTBNOFXSA-N 0.000 description 1
- KSHLSVFVBKOAGZ-SEIMFJOUSA-N CCC[C@@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@@]2(CC)O)O Chemical compound CCC[C@@H]([C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@@]2(CC)O)O KSHLSVFVBKOAGZ-SEIMFJOUSA-N 0.000 description 1
- WFYCHZYLSSPFGD-FUVMXNIJSA-N CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(CC)O Chemical compound CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(CC)O WFYCHZYLSSPFGD-FUVMXNIJSA-N 0.000 description 1
- YMXURWIGIPQLQX-MCDYBCKMSA-N CC[C@](C)(CC1)C[C@H](CC2)C1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(C)O Chemical compound CC[C@](C)(CC1)C[C@H](CC2)C1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(C)O YMXURWIGIPQLQX-MCDYBCKMSA-N 0.000 description 1
- MMOPLFLJKIEUAK-OIRAMGMESA-N CC[C@](CC1)(CC(CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CCC(C)(C)C)O)O Chemical compound CC[C@](CC1)(CC(CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CCC(C)(C)C)O)O MMOPLFLJKIEUAK-OIRAMGMESA-N 0.000 description 1
- MMOPLFLJKIEUAK-FJGKJTDNSA-N CC[C@](CC1)(C[C@@H](CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CCC(C)(C)C)O)O Chemical compound CC[C@](CC1)(C[C@@H](CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CCC(C)(C)C)O)O MMOPLFLJKIEUAK-FJGKJTDNSA-N 0.000 description 1
- ZMBKTXPTPXLEOH-ITCRALBASA-N CC[C@](CC1)(C[C@@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)C1(C)[C@H]2[C@H](C)[C@@H](CC1CCC(C)(C)CC1)O)O Chemical compound CC[C@](CC1)(C[C@@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)C1(C)[C@H]2[C@H](C)[C@@H](CC1CCC(C)(C)CC1)O)O ZMBKTXPTPXLEOH-ITCRALBASA-N 0.000 description 1
- XTHODKDFGNFXQY-NHKVCJDJSA-N CC[C@](CC1)(C[C@@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(CCC(C)C)O)O Chemical compound CC[C@](CC1)(C[C@@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(CCC(C)C)O)O XTHODKDFGNFXQY-NHKVCJDJSA-N 0.000 description 1
- MMOPLFLJKIEUAK-FUQMBPRTSA-N CC[C@](CC1)(C[C@@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CCC(C)(C)C)O)O Chemical compound CC[C@](CC1)(C[C@@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CCC(C)(C)C)O)O MMOPLFLJKIEUAK-FUQMBPRTSA-N 0.000 description 1
- XTHODKDFGNFXQY-IUANGPJYSA-N CC[C@](CC1)(C[C@@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CCC(C)C)O)O Chemical compound CC[C@](CC1)(C[C@@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CCC(C)C)O)O XTHODKDFGNFXQY-IUANGPJYSA-N 0.000 description 1
- CXCNRBTWNQJPSS-HNOAHRESSA-N CC[C@](CC1)(C[C@@H]2CCC[C@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)C(CCC(C)C)=O)[C@H]4[C@]1(C)C2)O Chemical compound CC[C@](CC1)(C[C@@H]2CCC[C@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)C(CCC(C)C)=O)[C@H]4[C@]1(C)C2)O CXCNRBTWNQJPSS-HNOAHRESSA-N 0.000 description 1
- LXDFJXGLJCJAAY-ZDXIWEEFSA-N CC[C@](CC1)(C[C@@](C)(CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(C)=C)O Chemical compound CC[C@](CC1)(C[C@@](C)(CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(C)=C)O LXDFJXGLJCJAAY-ZDXIWEEFSA-N 0.000 description 1
- MLLMQDYGSQUIPD-QOXBSLISSA-N CC[C@](CC1)(C[C@@](C)(CCC2)[C@@]1(C)[C@@H](CC1)[C@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CO)O Chemical compound CC[C@](CC1)(C[C@@](C)(CCC2)[C@@]1(C)[C@@H](CC1)[C@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CO)O MLLMQDYGSQUIPD-QOXBSLISSA-N 0.000 description 1
- DEMKCLDCAWHMRS-DWYRLTNLSA-N CC[C@](CC1)(C[C@H](CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)C2[C@H](C)[C@@H](C/C=C/C)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)C2[C@H](C)[C@@H](C/C=C/C)O)O DEMKCLDCAWHMRS-DWYRLTNLSA-N 0.000 description 1
- RRXJRMVBCVZUQQ-BQSOLNCTSA-N CC[C@](CC1)(C[C@H](CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(C(F)(F)F)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(C(F)(F)F)O)O RRXJRMVBCVZUQQ-BQSOLNCTSA-N 0.000 description 1
- LAAXFNFKNDNRIA-MEGMWTOASA-N CC[C@](CC1)(C[C@H](CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CC1CCOCC1)OC(c1ccccc1)=O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)C1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CC1CCOCC1)OC(c1ccccc1)=O)O LAAXFNFKNDNRIA-MEGMWTOASA-N 0.000 description 1
- IBZRXRJSZJGKHF-AYRJBCGGSA-N CC[C@](CC1)(C[C@H](CC2)C[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CCC(C)C)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)C[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CCC(C)C)O)O IBZRXRJSZJGKHF-AYRJBCGGSA-N 0.000 description 1
- JPIPZCCKRIXWIX-NETLVXKSSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)C1(C)[C@H]2[C@H](C)C(C)(C)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)C1(C)[C@H]2[C@H](C)C(C)(C)O)O JPIPZCCKRIXWIX-NETLVXKSSA-N 0.000 description 1
- RRXJRMVBCVZUQQ-ACQCPCJKSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)C1(C)[C@H]2[C@H](C)[C@@H](C(F)(F)F)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)C1(C)[C@H]2[C@H](C)[C@@H](C(F)(F)F)O)O RRXJRMVBCVZUQQ-ACQCPCJKSA-N 0.000 description 1
- DEMKCLDCAWHMRS-AILGPIEASA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)C2[C@H](C)[C@@H](C/C=C/C)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)C2[C@H](C)[C@@H](C/C=C/C)O)O DEMKCLDCAWHMRS-AILGPIEASA-N 0.000 description 1
- DNTPXVCILGUZSG-QHHSCXDJSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(c1cnccc1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(c1cnccc1)O)O DNTPXVCILGUZSG-QHHSCXDJSA-N 0.000 description 1
- DEMKCLDCAWHMRS-QAOFEEAASA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](C/C=C/C)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](C/C=C/C)O)O DEMKCLDCAWHMRS-QAOFEEAASA-N 0.000 description 1
- DNTPXVCILGUZSG-CHVUIHIUSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](c1cnccc1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)C2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](c1cnccc1)O)O DNTPXVCILGUZSG-CHVUIHIUSA-N 0.000 description 1
- NHWJYBRDJYWRNA-NHCPRLIASA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)C2[C@H](C)C(CC#CC)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)C2[C@H](C)C(CC#CC)O)O NHWJYBRDJYWRNA-NHCPRLIASA-N 0.000 description 1
- AGJQCAFCSXJAAY-GJEOOBOISA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)C2[C@H](C)[C@@H](CC1C(C)C1)OC(c1ccccc1)=O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)C2[C@H](C)[C@@H](CC1C(C)C1)OC(c1ccccc1)=O)O AGJQCAFCSXJAAY-GJEOOBOISA-N 0.000 description 1
- KLXDLTPNNUAJHZ-YGAFNDJJSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(C)C)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(C)C)O KLXDLTPNNUAJHZ-YGAFNDJJSA-N 0.000 description 1
- HYGVGEBEBPIPTN-SLJBZNGBSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(C1CCCC1)=O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C(C1CCCC1)=O)O HYGVGEBEBPIPTN-SLJBZNGBSA-N 0.000 description 1
- SHWLCNPFWIHDAE-SVKFCWHLSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C=O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)C=O)O SHWLCNPFWIHDAE-SVKFCWHLSA-N 0.000 description 1
- QEDMBYBMAUZUNO-SVKFCWHLSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CO)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CO)O QEDMBYBMAUZUNO-SVKFCWHLSA-N 0.000 description 1
- HKUMMQSYMLBRLY-QWGAXUBESA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](C1CCCC1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](C1CCCC1)O)O HKUMMQSYMLBRLY-QWGAXUBESA-N 0.000 description 1
- NHWJYBRDJYWRNA-ZRINNVNMSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC#CC)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC#CC)O)O NHWJYBRDJYWRNA-ZRINNVNMSA-N 0.000 description 1
- RDPWTFYCELMBAU-ISULHTTDSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC1C(C)C1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC1C(C)C1)O)O RDPWTFYCELMBAU-ISULHTTDSA-N 0.000 description 1
- UHGKSLFLYBPCIQ-NYHHFTEHSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC1CCOCC1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC1CCOCC1)O)O UHGKSLFLYBPCIQ-NYHHFTEHSA-N 0.000 description 1
- RDPWTFYCELMBAU-JHEJNLGOSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC1[C@H](C)C1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CC1[C@H](C)C1)O)O RDPWTFYCELMBAU-JHEJNLGOSA-N 0.000 description 1
- XTHODKDFGNFXQY-PCFYLMMQSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CCC(C)C)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](CCC(C)C)O)O XTHODKDFGNFXQY-PCFYLMMQSA-N 0.000 description 1
- CBGKWMNZFRYMGG-PFAPXYECSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](c1ccccc1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](c1ccccc1)O)O CBGKWMNZFRYMGG-PFAPXYECSA-N 0.000 description 1
- DNTPXVCILGUZSG-QWGAXUBESA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](c1cnccc1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@@H](c1cnccc1)O)O DNTPXVCILGUZSG-QWGAXUBESA-N 0.000 description 1
- SKTRUACPEULOHK-MXPAZZJCSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](C1=CCCN=C1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](C1=CCCN=C1)O)O SKTRUACPEULOHK-MXPAZZJCSA-N 0.000 description 1
- HKUMMQSYMLBRLY-MXPAZZJCSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](C1CCCC1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](C1CCCC1)O)O HKUMMQSYMLBRLY-MXPAZZJCSA-N 0.000 description 1
- ZMBKTXPTPXLEOH-PHAGMDMYSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CC1CCC(C)(C)CC1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CC1CCC(C)(C)CC1)O)O ZMBKTXPTPXLEOH-PHAGMDMYSA-N 0.000 description 1
- UHGKSLFLYBPCIQ-PFAPXYECSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CC1CCOCC1)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)[C@H](CC1CCOCC1)O)O UHGKSLFLYBPCIQ-PFAPXYECSA-N 0.000 description 1
- WLBYZMFMJNOBHD-UUQBUZOOSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H]2[C@@]1(C)C(C1)([C@H](C)[C@H](C3CC3)O)C1C2)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H]2[C@@]1(C)C(C1)([C@H](C)[C@H](C3CC3)O)C1C2)O WLBYZMFMJNOBHD-UUQBUZOOSA-N 0.000 description 1
- SYXIUHZPFDLQNH-CWPUANMOSA-N CC[C@](CCC=C)(C[C@@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1[C@H](C)[C@H](CCC(C)C)OC(c1ccccc1)=O)O Chemical compound CC[C@](CCC=C)(C[C@@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1[C@H](C)[C@H](CCC(C)C)OC(c1ccccc1)=O)O SYXIUHZPFDLQNH-CWPUANMOSA-N 0.000 description 1
- YTBLREZGWNTFFM-KWSNYPAUSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)C=O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)C=O)[C@H]4[C@@]2(C)CC1)O YTBLREZGWNTFFM-KWSNYPAUSA-N 0.000 description 1
- RQMYVXGDUQAYIL-ZQZWCTIGSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@@H](C(C)C)O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@@H](C(C)C)O)[C@H]4[C@@]2(C)CC1)O RQMYVXGDUQAYIL-ZQZWCTIGSA-N 0.000 description 1
- HYGVDBPCZCKKTI-OSAXKMCZSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@@H](CC3CCC(C)(C)CC3)O)C4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@@H](CC3CCC(C)(C)CC3)O)C4[C@@]2(C)CC1)O HYGVDBPCZCKKTI-OSAXKMCZSA-N 0.000 description 1
- WTSBOJOWOREQJN-VRKZMMNLSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@@H](CCC(C)C)O)C4[C@H]2CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@@H](CCC(C)C)O)C4[C@H]2CC1)O WTSBOJOWOREQJN-VRKZMMNLSA-N 0.000 description 1
- GDOCIRBCEBKWRM-LQNWKCFRSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@H](C(F)(F)F)O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@H](C(F)(F)F)O)[C@H]4[C@@]2(C)CC1)O GDOCIRBCEBKWRM-LQNWKCFRSA-N 0.000 description 1
- VDCYYXOILZFYDK-WOKMFAOSSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@H](CCC(C)(C)CCC[C@]3(CC5=CC[C@@H]([C@H](CC6)[C@](C)(CC7)[C@H]6[C@H](C)[C@@H](CCC6CC6)O)C7[C@@]5(C)CC3)O)O)C4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@H](CCC(C)(C)CCC[C@]3(CC5=CC[C@@H]([C@H](CC6)[C@](C)(CC7)[C@H]6[C@H](C)[C@@H](CCC6CC6)O)C7[C@@]5(C)CC3)O)O)C4[C@@]2(C)CC1)O VDCYYXOILZFYDK-WOKMFAOSSA-N 0.000 description 1
- KOTRRGYINNJAJT-FVEMDCNFSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@H](CCC(C)C)O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)[C@H](CCC(C)C)O)[C@H]4[C@@]2(C)CC1)O KOTRRGYINNJAJT-FVEMDCNFSA-N 0.000 description 1
- DLUQNACUKJGTBL-JFGMHRGESA-N C[C@@H]([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@H]1C[C@@]2(COC)O)C(C(F)(F)F)=O Chemical compound C[C@@H]([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@H]1C[C@@]2(COC)O)C(C(F)(F)F)=O DLUQNACUKJGTBL-JFGMHRGESA-N 0.000 description 1
- AOGZBEXXRZFBJI-XITJBVPXSA-N C[C@H](C(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@@]1(C)[C@H]2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 Chemical compound C[C@H](C(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@@]1(C)[C@H]2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 AOGZBEXXRZFBJI-XITJBVPXSA-N 0.000 description 1
- IPVHWRUWDLGGAR-VYDHAAAYSA-N C[C@H]([C@@H](/C=C/c1ccccc1)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O Chemical compound C[C@H]([C@@H](/C=C/c1ccccc1)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O IPVHWRUWDLGGAR-VYDHAAAYSA-N 0.000 description 1
- QXUDDXOAZXGBTP-IRVLRIJXSA-N C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)C(C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@@]2(C)O Chemical compound C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)C(C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@@]2(C)O QXUDDXOAZXGBTP-IRVLRIJXSA-N 0.000 description 1
- AOGZBEXXRZFBJI-BMJWNOCZSA-N C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@@]1(C)[C@H]2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 Chemical compound C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@@]1(C)[C@H]2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 AOGZBEXXRZFBJI-BMJWNOCZSA-N 0.000 description 1
- RMYKYTTUORPTQY-LWFQBTSBSA-N C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@H]1C[C@@]2(C(OC)=C)O Chemical compound C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@H]1C[C@@]2(C(OC)=C)O RMYKYTTUORPTQY-LWFQBTSBSA-N 0.000 description 1
- UGQHKWIHGLUCQX-XJEIYQMMSA-N C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@H]1C[C@@]2(COC)O Chemical compound C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@H]1C[C@@]2(COC)O UGQHKWIHGLUCQX-XJEIYQMMSA-N 0.000 description 1
- PPTIGLUUEPIAHP-VTYUFCCLSA-N C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@](C2)(C(F)(F)F)O)C2=CC1 Chemical compound C[C@H]([C@@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@](C2)(C(F)(F)F)O)C2=CC1 PPTIGLUUEPIAHP-VTYUFCCLSA-N 0.000 description 1
- XZBOEINLXMMYQO-CWJVLOTHSA-N C[C@H]([C@@H](C)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O Chemical compound C[C@H]([C@@H](C)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O XZBOEINLXMMYQO-CWJVLOTHSA-N 0.000 description 1
- GKFGRNSGIADUHS-WBFNXHGNSA-N C[C@H]([C@@H](C[C@@H](c1ccccc1)O)O)[C@@H](CC1)C(C)(CC2)[C@@H]1C(CC1)[C@H]2C(C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O Chemical compound C[C@H]([C@@H](C[C@@H](c1ccccc1)O)O)[C@@H](CC1)C(C)(CC2)[C@@H]1C(CC1)[C@H]2C(C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O GKFGRNSGIADUHS-WBFNXHGNSA-N 0.000 description 1
- QKVMMQDHHQAODO-HQKGHCPOSA-N C[C@H]([C@H](C(F)(F)F)O)C(CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 Chemical compound C[C@H]([C@H](C(F)(F)F)O)C(CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 QKVMMQDHHQAODO-HQKGHCPOSA-N 0.000 description 1
- QKVMMQDHHQAODO-LQNWKCFRSA-N C[C@H]([C@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 Chemical compound C[C@H]([C@H](C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 QKVMMQDHHQAODO-LQNWKCFRSA-N 0.000 description 1
- POGBNOOJJPAJSX-UUBFCIGZSA-N C[C@H]([C@H](C[C@@H](c1ccc(CC[C@](CC2)(C[C@H](CC3)[C@@]2(C)[C@@H](CC2)[C@@H]3[C@H](CC3)[C@@]2(C)[C@H]3[C@H](C)C(C)(C)O)O)cc1)O)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O Chemical compound C[C@H]([C@H](C[C@@H](c1ccc(CC[C@](CC2)(C[C@H](CC3)[C@@]2(C)[C@@H](CC2)[C@@H]3[C@H](CC3)[C@@]2(C)[C@H]3[C@H](C)C(C)(C)O)O)cc1)O)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O POGBNOOJJPAJSX-UUBFCIGZSA-N 0.000 description 1
- GKFGRNSGIADUHS-AXRKLKTPSA-N C[C@H]([C@H](C[C@@H](c1ccccc1)O)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O Chemical compound C[C@H]([C@H](C[C@@H](c1ccccc1)O)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C(F)(F)F)O GKFGRNSGIADUHS-AXRKLKTPSA-N 0.000 description 1
- RWRYWDDTMBCLHT-BULSNMFISA-N C[C@](CC1)([C@@H](CC2)[C@@H]3[C@H]1[C@@](C)(CCC(C1)=O)[C@]1(C)CCC3)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@@H]3[C@H]1[C@@](C)(CCC(C1)=O)[C@]1(C)CCC3)[C@H]2C(C)=O RWRYWDDTMBCLHT-BULSNMFISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000126A JP7304444B2 (ja) | 2016-10-18 | 2022-01-04 | オキシステロールおよびその使用方法 |
| JP2023041898A JP2023063535A (ja) | 2016-10-18 | 2023-03-16 | オキシステロールおよびその使用方法 |
| JP2025162058A JP2025184962A (ja) | 2016-10-18 | 2025-09-29 | オキシステロールおよびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409768P | 2016-10-18 | 2016-10-18 | |
| US201662409756P | 2016-10-18 | 2016-10-18 | |
| US62/409,768 | 2016-10-18 | ||
| US62/409,756 | 2016-10-18 | ||
| PCT/US2017/057276 WO2018075698A1 (en) | 2016-10-18 | 2017-10-18 | Oxysterols and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000126A Division JP7304444B2 (ja) | 2016-10-18 | 2022-01-04 | オキシステロールおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532079A true JP2019532079A (ja) | 2019-11-07 |
| JP2019532079A5 JP2019532079A5 (enExample) | 2020-11-26 |
Family
ID=60263022
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520737A Withdrawn JP2019532079A (ja) | 2016-10-18 | 2017-10-18 | オキシステロールおよびその使用方法 |
| JP2022000126A Active JP7304444B2 (ja) | 2016-10-18 | 2022-01-04 | オキシステロールおよびその使用方法 |
| JP2023041898A Pending JP2023063535A (ja) | 2016-10-18 | 2023-03-16 | オキシステロールおよびその使用方法 |
| JP2025162058A Pending JP2025184962A (ja) | 2016-10-18 | 2025-09-29 | オキシステロールおよびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000126A Active JP7304444B2 (ja) | 2016-10-18 | 2022-01-04 | オキシステロールおよびその使用方法 |
| JP2023041898A Pending JP2023063535A (ja) | 2016-10-18 | 2023-03-16 | オキシステロールおよびその使用方法 |
| JP2025162058A Pending JP2025184962A (ja) | 2016-10-18 | 2025-09-29 | オキシステロールおよびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11111266B2 (enExample) |
| EP (3) | EP4105223B1 (enExample) |
| JP (4) | JP2019532079A (enExample) |
| KR (3) | KR20230051723A (enExample) |
| CN (3) | CN115322238A (enExample) |
| AU (3) | AU2017345399B2 (enExample) |
| DK (1) | DK4105223T3 (enExample) |
| ES (2) | ES3038660T3 (enExample) |
| IL (3) | IL293231B2 (enExample) |
| MA (1) | MA46565A (enExample) |
| MX (2) | MX2019004679A (enExample) |
| RU (1) | RU2019115112A (enExample) |
| TW (3) | TW202446399A (enExample) |
| WO (1) | WO2018075698A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4245369A3 (en) | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MX362544B (es) | 2013-03-13 | 2019-01-24 | Sage Therapeutics Inc | Esteroides neuroactivos y metodos para su uso. |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| MA42410B1 (fr) | 2015-07-06 | 2021-04-30 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| SI3812392T1 (sl) | 2015-07-06 | 2025-09-30 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| HUE059491T2 (hu) | 2016-04-01 | 2022-11-28 | Sage Therapeutics Inc | Oxiszterolok és azok alkalmazási eljárásai |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3481846T (pt) | 2016-07-07 | 2021-08-13 | Sage Therapeutics Inc | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| MA46566A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| EP4105223B1 (en) * | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN111560045A (zh) * | 2020-06-23 | 2020-08-21 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成石胆酸的方法 |
| CN112375117A (zh) * | 2020-11-14 | 2021-02-19 | 湖南科瑞生物制药股份有限公司 | 石胆酸及其中间体的制备方法 |
| CN113651866B (zh) * | 2021-08-02 | 2023-07-04 | 王涛 | 一种以21-羟基-20-甲基孕甾-4-烯-3-酮为原料合成胆固醇的新方法 |
| US20250387409A1 (en) * | 2021-11-10 | 2025-12-25 | Umecrine Cognition Ab | 3-beta-hydroxy-3-alpha-ethyl steroids for modulation of the alpha-3 subtype of the gabaa receptor |
| EP4433475A4 (en) | 2021-11-15 | 2026-01-14 | Hepaitech Beijing Biopharma Tech Co Ltd | POLYCYCLIC COMPOUNDS AND THEIR PROCESSES |
| WO2023192421A1 (en) | 2022-03-30 | 2023-10-05 | Donaldson Company, Inc. | System and method for reclaiming solvent |
| EP4547256A1 (en) * | 2022-07-01 | 2025-05-07 | Intercept Pharmaceuticals, Inc. | Methods for ameliorating cognitive impairment using bile acid derivatives |
| TW202430133A (zh) * | 2022-11-21 | 2024-08-01 | 美商賽吉醫療公司 | 負ｎｍｄａ調節化合物及其使用方法 |
| CN115974950A (zh) * | 2022-12-23 | 2023-04-18 | 上海彩迩文生化科技有限公司 | 一种3-烷基化的甾体中间体及其制备和应用 |
| WO2025020191A1 (zh) * | 2023-07-27 | 2025-01-30 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
| WO2025250816A1 (en) * | 2024-05-29 | 2025-12-04 | Sage Therapeutics, Inc. | Agents for delivering nmda receptor modulating compounds and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014526469A (ja) * | 2011-09-08 | 2014-10-06 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| JPH03500049A (ja) | 1987-08-25 | 1991-01-10 | ジー、ケルビン・ダブリュー | ストレス、不安および発作活性の緩和のための組成物および方法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| KR100338287B1 (ko) | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| GEP20002033B (en) | 1994-11-23 | 2000-04-10 | Cocensys Inc Us | Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| ES2235187T3 (es) | 1995-06-06 | 2005-07-01 | Euro-Celtique S.A. | Esteroides neuroactivos de las series del androstano y el pregnano. |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| WO1997000884A1 (en) | 1995-06-23 | 1997-01-09 | Novo Nordisk A/S | Meiosis regulating compounds |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP1077933A1 (en) | 1998-05-11 | 2001-02-28 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| IL146230A0 (en) | 1999-04-29 | 2002-07-25 | Purdue Pharma Ltd | 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US6376530B1 (en) | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| WO2002090375A2 (en) | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
| EP1450816A4 (en) | 2001-11-08 | 2008-02-13 | Univ Chicago | METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE |
| CA2468989A1 (en) | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| WO2003082893A2 (en) | 2002-03-27 | 2003-10-09 | Phytopharm Plc | Theraputic methods and uses of sapogenins and their derivatives |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| WO2006050165A2 (en) | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| IN2014DN02014A (enExample) | 2006-11-21 | 2015-07-10 | Umecrine Ab | |
| KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논 |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| JP2011502974A (ja) | 2007-11-06 | 2011-01-27 | ナームローゼ・フエンノートチヤツプ・オルガノン | ヒトにおけるホルモン抑制の方法 |
| US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| JP2011520815A (ja) | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| US20140335050A1 (en) | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| AU2012323888A1 (en) * | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| WO2014115167A2 (en) | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| EA031905B1 (ru) | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| MX362544B (es) | 2013-03-13 | 2019-01-24 | Sage Therapeutics Inc | Esteroides neuroactivos y metodos para su uso. |
| EP3865135A3 (en) | 2013-03-13 | 2021-11-03 | Sage Therapeutics, Inc. | Neuroactive steroids for use in therapy |
| EP2986624B1 (en) * | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
| AU2014324961A1 (en) | 2013-09-25 | 2016-04-14 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Highly potent glucocorticoids |
| WO2015120280A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| BR112017007053A2 (pt) | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| WO2017007832A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| SI3812392T1 (sl) | 2015-07-06 | 2025-09-30 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| MA42410B1 (fr) | 2015-07-06 | 2021-04-30 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| HUE059491T2 (hu) | 2016-04-01 | 2022-11-28 | Sage Therapeutics Inc | Oxiszterolok és azok alkalmazási eljárásai |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3481846T (pt) | 2016-07-07 | 2021-08-13 | Sage Therapeutics Inc | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| MA46566A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| JP7224307B2 (ja) | 2017-06-23 | 2023-02-17 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁酸誘導体の調製のための方法及び中間体 |
| JP7312169B2 (ja) | 2017-11-10 | 2023-07-20 | マリナス ファーマシューティカルズ インコーポレイテッド | 遺伝性てんかん性障害の処置に使用するガナキソロン |
-
2017
- 2017-10-18 EP EP22175674.5A patent/EP4105223B1/en active Active
- 2017-10-18 EP EP25173033.9A patent/EP4616908A3/en active Pending
- 2017-10-18 KR KR1020237012221A patent/KR20230051723A/ko not_active Ceased
- 2017-10-18 IL IL293231A patent/IL293231B2/en unknown
- 2017-10-18 AU AU2017345399A patent/AU2017345399B2/en active Active
- 2017-10-18 ES ES22175674T patent/ES3038660T3/es active Active
- 2017-10-18 MX MX2019004679A patent/MX2019004679A/es unknown
- 2017-10-18 TW TW113106000A patent/TW202446399A/zh unknown
- 2017-10-18 DK DK22175674.5T patent/DK4105223T3/da active
- 2017-10-18 KR KR1020257012306A patent/KR20250054838A/ko active Pending
- 2017-10-18 CN CN202210876413.0A patent/CN115322238A/zh active Pending
- 2017-10-18 RU RU2019115112A patent/RU2019115112A/ru unknown
- 2017-10-18 MA MA046565A patent/MA46565A/fr unknown
- 2017-10-18 IL IL320521A patent/IL320521A/en unknown
- 2017-10-18 TW TW111123637A patent/TWI836485B/zh active
- 2017-10-18 ES ES17794488T patent/ES2968140T3/es active Active
- 2017-10-18 CN CN202210425686.3A patent/CN114891056A/zh active Pending
- 2017-10-18 JP JP2019520737A patent/JP2019532079A/ja not_active Withdrawn
- 2017-10-18 TW TW106135795A patent/TWI772331B/zh active
- 2017-10-18 EP EP17794488.1A patent/EP3529256B1/en active Active
- 2017-10-18 CN CN201780076791.8A patent/CN110072874B/zh active Active
- 2017-10-18 US US16/343,238 patent/US11111266B2/en active Active
- 2017-10-18 WO PCT/US2017/057276 patent/WO2018075698A1/en not_active Ceased
- 2017-10-18 KR KR1020197014258A patent/KR102521573B1/ko active Active
-
2019
- 2019-04-17 MX MX2022005160A patent/MX2022005160A/es unknown
- 2019-04-17 IL IL266092A patent/IL266092B2/en unknown
-
2021
- 2021-07-27 US US17/386,364 patent/US11613556B2/en active Active
-
2022
- 2022-01-04 JP JP2022000126A patent/JP7304444B2/ja active Active
- 2022-02-08 AU AU2022200810A patent/AU2022200810B2/en active Active
-
2023
- 2023-02-06 US US18/106,073 patent/US12180247B2/en active Active
- 2023-03-16 JP JP2023041898A patent/JP2023063535A/ja active Pending
-
2024
- 2024-04-29 AU AU2024202773A patent/AU2024202773A1/en active Pending
- 2024-11-13 US US18/945,876 patent/US20250179112A1/en active Pending
-
2025
- 2025-09-29 JP JP2025162058A patent/JP2025184962A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014526469A (ja) * | 2011-09-08 | 2014-10-06 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7304444B2 (ja) | オキシステロールおよびその使用方法 | |
| JP6966486B2 (ja) | オキシステロールおよびその使用方法 | |
| JP2019532078A (ja) | オキシステロールおよびその使用方法 | |
| JP2022036260A (ja) | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 | |
| CA3041077C (en) | Oxysterols and methods of use thereof | |
| HK40083913A (en) | Oxysterols and methods of use thereof | |
| HK40006309B (en) | Oxysterols and methods of use thereof | |
| HK40006309A (en) | Oxysterols and methods of use thereof | |
| BR122022000002B1 (pt) | Compostos oxiesteróis, composição farmacêutica e usos dos mesmos | |
| BR122024020803B1 (pt) | Compostos oxiesteróis, composição farmacêutica e uso dos mesmos | |
| BR122024020803A2 (pt) | Compostos oxiesteróis, composição farmacêutica e uso dos mesmos | |
| BR112019008069B1 (pt) | Compostos oxiesteróis, composições farmacêuticas e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201014 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201014 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220526 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20220825 |